OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study
Keywords: atopic dermatitis; atopic eczema; OPA-15406; phosphodiesterase type 4 inhibitor; topical agents; topical calcineurin inhibitor; AD; atopic dermatitis; BSA; body surface area; DLQI; Dermatology Life Quality Index; EASI; Eczema Area and Severity Index; IGA;